ALZPATH
ALZpath is a biotechnology company that provides novel diagnostic solutions for Alzheimer’s disease.
ALZPATH
Industry:
Biotechnology Life Science Therapeutics
Founded:
2020-01-01
Address:
Carlsbad, California, United States
Country:
United States
Website Url:
http://www.alzpath.bio
Total Employee:
11+
Status:
Active
Contact:
1 844 723 7228
Email Addresses:
[email protected]
Similar Organizations
Cognoptix
Cognoptix develops non-invasive eye tests for the early diagnosis of alzheimer disease.
Flightpath Biosciences
Flightpath Biosciences is a biotechnology company that develops medications to treat rare infectious diseases.
ImmuneCyte
ImmuneCyte develops cell and gene therapeutics for the aging-related diseases
REMD Biotherapeutics
REMD Biotherapeutics provides medications for chronic illnesses such as metabolic diseases.
Shuimu BioSciences
Shuimu BioSciences provides one-stop solutions for cryo-EM-Powered drug discovery.
Investors List
Alzheimer's Drug Discovery Foundation
Alzheimer's Drug Discovery Foundation investment in Grant - ALZpath
Gareth DeSanctis
Gareth DeSanctis investment in Convertible Note - ALZpath
Official Site Inspections
http://www.alzpath.bio
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ALZpath"
ALZpath 2025 Company Profile: Valuation, Funding
Jul 19, 2023 www.alzpath.bio. Ownership Status. Privately Held (backing) Financing Status. Venture Capital-Backed. Corporate Office. 2292 Faraday …See details»
ALZpath - Crunchbase Company Profile & Funding
Organization. ALZpath . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Contact Email [email protected]; Phone …See details»
ALZpath Inc. - LinkedIn
ALZpath is a passionate and focused group of medical researchers, healthcare professionals, and renowned group of scientific advisors dedicated to transforming the Alzheimer’s disease ecosystem ...See details»
ALZpath: Revenue, Worth, Valuation & Competitors 2025
About ALZpath. ALZpath is a Biotechnology Research related company based in Carlsbad with 12 employees and an estimated revenue of $852.5K. ALZpath is a passionate and focused group …See details»
Alamar Biosciences and ALZpath, Inc. Announce …
Feb 29, 2024 Fremont, CA – Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce a strategic supply agreement with ALZpath, a leading developer of …See details»
ALZPath, Inc. | Alzheimer's Drug Discovery Foundation
Jul 15, 2023 ALZpath intends to develop and validate (using proprietary reagents), a plasma pTau217 laboratory developed test (LDT) and launch for clinical use. ... View all funding to this …See details»
ALZpath Adds Biotech Veteran to Board of Directors and Names …
Mar 25, 2025 These include Roche, Beckman Coulter, Bio-Techne, Alamar Biosciences, and Quanterix. Additionally, ALZpath partners with world-class laboratories, such as Neurocode, to …See details»
ALZpath - Accelerating Novel Diagnostic Solutions for …
Apr 7, 2025 Data Showcasing ALZpath’s Proprietary pTau217 Antibody at AD/PD™ 2025 Demonstrates High Rate of Reliability and Scalability for Alzheimer’s Disease Research and Diagnosis. Findings from Studies on Blood …See details»
ALZpath Is Powering a New Wave of Blood-Based …
Sep 5, 2024 ALZpath recently announced a partnership with Roche that cemented the company’s vision for working with the world’s leading pharmaceutical companies, rather than competing as a drug platform …See details»
The Power of Knowing Early about Alzheimer’s | Stead Impact
May 13, 2025 Dana: ALZpath co-founder Dr. Eric Reiman, a leading Alzheimer’s researcher and CEO of the Banner Alzheimer’s Institute, collaborated on a groundbreaking study …See details»
Researchers | Alzheimer's Disease | ALZpath
The ALZpath pTau217 Assay enables researchers to measure pTau217 levels reliably, opening doors to groundbreaking advancements in Alzheimer’s research. Highly Sensitive Assay: …See details»
Contact Us - ALZpath
Contact Us Interested in ordering our ALZpath pTau217 assay or have samples you might like analyzed? Would you like to learn more about ALZpath? Please complete the form below and …See details»
Healthcare Providers | Alzheimer's Disease - ALZpath
ALZpath has established the robust and scalable plasma-based ultra-sensitive assay for the leading blood-based biomarker for Alzheimer’s Disease, pTau217. Over 40,000 tests have …See details»
ALZpath pTau217: Multi‐cohort performance, cross‐assay …
Jan 9, 2025 The ALZpath pTau217 assay is an ultra-sensitive blood-based test developed on the semi-automated single-molecule array Simoa platform; it is the first commercially available …See details»
pTau217 Antibody Demonstrates High Rate of Reliability and …
Apr 1, 2025 ALZpath’s pTau217 antibody enables highly sensitive blood-based detection of a key Alzheimer’s biomarker, supporting early diagnosis before symptoms appear. ... Bio …See details»
ALZpath licenses Alzheimer’s diagnosis tech to Roche
Jun 11, 2025 The Swiss group has taken a license to use an antibody developed by ALZpath against a form of phosphorylated tau protein – pTau217 – for the development and …See details»
New Blood Test for Early Alzheimer's Detection - Alzra
Feb 28, 2024 In addition, they designed the ALZpath pTau217 assay, which is exclusive to researchers and enables them to identify this particular kind of tau through a blood test [5]. An …See details»
Welcome to BIO 2025: Collaboration can't wait. | BIO
2 days ago As we kick off BIO 2025, the world’s largest biotech gathering, BIO emphasizes that collaboration can’t wait. Today’s theme: Collaboration—between government and industry, …See details»
BIO 2025: Progress can't wait. | BIO - bio.org
1 day ago BIO 2025 started with a multi-panel session featuring officials from the Administration for Strategic Preparedness and Response (ASPR) and the Department of Defense about how …See details»
ALZpath| Webinar
Clinical Evaluation Data for ALZpath’s Plasma pTau217 Assay; Results from Wisconsin’s Registry for Alzheimer’s Prevention (WRAP) related to pTau217; Practical Aspects of High-throughput …See details»